BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of more than 15 transformative drugs ranging from pre-clinical to late stage development in multiple therapeutic areas including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/24/19 | $299,200,000 | Venture |
AIG Aisling Capital Cormorant Capital Hercules Capital KKR  Perceptive Advisors Viking Global Investors | undisclosed |
